SELECT COUNTRY

VIEW ALL

AFRICA

AMERICAS

ASIA

EUROPE

OCEANIA

ALGERIA ANGOLA ARGENTINA AUSTRALIA AZERBAIJAN BAHREIN BELGIUM BENIN BOLIVIA BOTSWANA BRAZIL BRUNEI BURKINA FASO CAMEROON CANADA CENTRAL AFRICAN REPUBLIC CHAD CHILE CHINA COLOMBIA COTE D’IVOIRE CZECH REPUBLIC DOMINICAN REPUBLIC DRC ECUADOR EGYPT ETHIOPIA FINLAND FRANCE GABON GHANA GREENLAND GUINEA HUNGARY ICELAND INDIA INDONESIA IRAN IRAQ ITALY KAZAKHSTAN KENYA KUWAIT LESOTHO LIBERIA MADAGASCAR MALAWI MALAYSIA MALI MAURITANIE MEXICO MONGOLIA MOROCCO MOZAMBIQUE NAMIBIA NETHERLANDS NICARAGUA NIGER NIGERIA NORWAY PANAMA PAPUA NEW GUINEA PERU PHILIPPINES POLAND QATAR REPUBLIC OF CONGO RUSSIA RWANDA SENEGAL SIERRA LEONA SINGAPORE SLOVENIA SOMALI SOUTH AFRICA SOUTH KOREA SPAIN SUDAN SWEDEN TAIWAN TANZANIA THAILAND TOGO TRINDAD & TOBAGO TURKEY TURKMENISTAN UAE UGANDA UKRAINE UNITED KINGDOM UNITED STATES VENEZUELA VIETNAM ZAMBIA ZIMBABWE

REPUBLIC OF CONGO: LATEST INTERVIEWS MORE INTERVIEWS

Hadley Natus

CHAIRMAN, TANTALEX LITHIUM RESOURCES CORP

"Mining tailings is not only the cleanest form of mining but also the cheapest: Except for rehabilitation costs, mining costs are negligible."

Mining

Republic of Congo

MACIG

Andrew van Zyl

MANAGING DIRECTOR, SRK SOUTH AFRICA

"Perhaps SRK’s most significant contribution to addressing ESG risk is its cross-disciplinary approach."

Mining

Republic of Congo

MACIG

Xavier “Jack” de Longueville

REGIONAL DIRECTOR AFRICA, ROBINSON INTERNATIONAL GROUP

Robinson International explains conditions for its analysis and testing operations in DRC.

ENI updates GBR on the progress of its operations across Sub-Saharan Africa.

REPUBLIC OF CONGO: LATEST ARTICLES

No Content Found

REPUBLIC OF CONGO: RECENTLY RELEASED PUBLICATIONS

No Content Found

RECENTLY PUBLISHED

United States Life Sciences 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.

MORE PREVIOUSLY PUBLISHED